Extensive testing, consultation with primary-care doctor key to proper treatment
A. Paul Chous, MA, OD, FAAO, CDE
The Diabetic Retinopathy Clinical Research Network (DRCR.net) supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders
An increasing number of patients diagnosed with diabetes are being prescribed insulin therapy.1
Several diabetes medications are now available for reducing blood glucose levels, with more on the horizon. Such drugs work by a variety of pharmacologic mechanisms.
The human microbiome refers to a diverse biological ecosystem of microorganisms residing within—and on the surface of—human beings.
The time to refer patients with diabetic retinopathy (DR) or diabetic macular edema (DME) depends on disease staging and location, especially now that ODs have new treatment options for lessening disease severity.
The U.S. Food and Drug Administration (FDA) in April 2018 gave its first approval of an artificial intelligence (AI) algorithm for the detection of diabetic retinopathy (DR) in the offices of non-ophthalmic healthcare practitioners.1
Non-eyecare practitioners will be screening your patients for diabetic retinopathy. Find out why this can help or hurt your patients and how you can help guide the process.
A new study shows that mean blood sugar levels as reflected by glycosylated hemoglobin (HbA1c) were strongly associated with cognitive decline and dementia.
ODs may wish to incorporate color vision testing when working with patients having diabetes. A. Paul Chous, MA, OD, FAAO, CDE, talks about the importance of these tests, incorporating them into day-to-day exams, and devices available.